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Deregulation of the spindle assembly
checkpoint is associated with paclitaxel
resistance in ovarian cancer
Taryne Chong1, Amila Sarac1, Cindy Q. Yao2, Linda Liao1, Nicola Lyttle1, Paul C. Boutros2,3,4,
John M. S. Bartlett1,5,6 and Melanie Spears1,5*
Abstract
Background: Ovarian cancer is the leading gynecologic cancer diagnosed in North America and because related
symptoms are not disease specific, this often leads to late detection, an advanced disease state, and the need for
chemotherapy. Ovarian cancer is frequently sensitive to chemotherapy at diagnosis but rapid development of drug
resistance leads to disease progression and ultimately death in the majority of patients.
Results: We have generated paclitaxel resistant ovarian cell lines from their corresponding native cell lines to determine
driver mechanisms of drug resistance using gene expression arrays. These paclitaxel resistant ovarian cells demonstrate:
(1) Increased IC50 for paclitaxel and docetaxel (10 to 75-fold) and cross-resistance to anthracyclines (2) Reduced cell
apoptosis in the presence of paclitaxel (3) Gene depletion involving mitotic regulators BUB1 mitotic checkpoint serine/
threonine kinase, cyclin BI (CCNB1), centromere protein E (CENPE), and centromere protein F (CENPF), and (4) Functional
data validating gene depletion among mitotic regulators.
Conclusions: We have generated model systems to explore drug resistance in ovarian cancer, which have revealed a
key pathway related to the spindle assembly checkpoint underlying paclitaxel resistance in ovarian cell lines.
Keywords: Spindle assembly checkpoint, Ovarian cancer, Paclitaxel, Mitotic checkpoint serine/threonine kinase (BUB1),
centromere protein E (CENPE), Centromere protein F (CENPF), Cyclin B1 (CCNB1)
Background
Each year approximately 158,000 women die of ovarian
cancer worldwide [1]. Ovarian cancer is the most common
gynecological cancer diagnosed in North America and has
one of the lowest survival rates among all cancers [2].
Symptoms are not disease specific and often overlap with
other common gastrointestinal and gynecological condi-
tions, which can result in late detection, an advanced dis-
ease state, and the need for chemotherapy [2–4]. Roughly
70% of ovarian cancers are sensitive to chemotherapy treat-
ment at diagnosis, but rapid development of drug resist-
ance and the inability to halt metastasis leads to treatment
failure and disease progression when detected at later
stages [4–6]. Paclitaxel is a frontline therapy used to treat
advanced ovarian cancer, and in many instances, paclitaxel
is combined with platinum based therapeutic drugs, such
as carboplatin to improve overall survival [4, 7]. Paclitaxel
inhibits cell replication by stabilizing microtubule assem-
bly, thereby promoting mitotic arrest at the spindle assem-
bly checkpoint [8–10]. Previous evidence points to
numerous components of the spindle assembly checkpoint
and mitotic regulation playing a major role in several can-
cers [11, 12]. We have generated isogenic paclitaxel resist-
ant cell lines from their corresponding native cell lines
which reflect the 3 most common ovarian histologic sub-
types, these include serous, clear cell and endometrioid
subtypes [2]. These pre-clinical models were used to ob-
serve cytotoxicity, cell cycle modulation and changes in
gene expression to examine the mechanisms driving drug
resistance. Lastly, through gene expression profiling we
have demonstrated disruption of the spindle assembly
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checkpoint in the paclitaxel resistant cell lines, indicating a
potential therapeutic pathway.
Methods
Cell lines and cell culture
Human ovarian cancer cell lines TOV21G (representing
clear cell ovarian carcinoma) and TOV112D (represent-
ing endometrioid adenocarcinoma) were purchased from
American Type Culture Collection (Manassas, VA). The
human ovarian epithelial-serous cell line COV504 was
purchased from Sigma Aldrich (St. Louis, MO). The
identity of each cell line was validated prior to use by
short tandem repeat genotyping at The Centre for Ap-
plied Genomics at The Hospital for Sick Children (To-
ronto, ON). All cell lines were cultured in Dulbecco’s
modified eagles’ medium (DMEM) supplemented with 2
mM glutamine and 10% heat inactivated fetal bovine
serum (FBS) from Life Technologies (Carlsbad, CA) and
maintained at 37°C in a 5% CO2 atmosphere. The fol-
lowing chemotherapeutic drugs: paclitaxel, docetaxel,
doxorubicin, epirubicin and carboplatin were purchased
from Sigma Aldrich (St. Louis, MO), dissolved in di-
methyl sulfoxide (DMSO) from Sigma Aldrich (St. Louis,
MO) and supplemented in complete media at increasing
concentrations. Cells were exposed to an incremental
dose escalation of paclitaxel (2 nM) for approximately 2
passages, up to a final concentration of 25 nM, once
paclitaxel resistance was achieved.
Cell viability and cytotoxicity assays
IC50 values were determined using the CCK-8 assay
from Dojindo Molecular Technologies (Rockville, MD).
Briefly, all cell suspensions were plated in 100 μl per well
across a 96-well plate, allowed to grow for 24 hours and
incubated at 37°C in a humidified 5% CO2 atmosphere.
Following a 24 hour incubation, cells were treated with
complete DMEM with 10% FBS and supplemented with
or without increasing concentrations of drugs (0, 0.3, 1,
3, 10, 30, 100, 1000 or 3000 nM) in DMSO. After 72
hours of exposure to varying drug concentrations, 10 μl
of the CCK-8 assay reagent was added to 90 μl DMEM
and the cells were incubated for an additional 4 hours at
37°C in a 5% CO2 atmosphere. The absorbance of each
sample was measured using a microplate reader at 450
nm from BioRad (Hercules, CA). Negative controls were
prepared using cell-free complete DMEM containing the
CCK-8 reagent.
Annexin V staining
Cultured cells were treated with or without paclitaxel for
24 hours prior to collection. According to the manufac-
turer’s protocol from eBioscience (San Diego, CA); cells
were washed once in 1X phosphate buffered saline (PBS)
and 1X Binding Buffer from eBioscience, then resuspended
in 1X Binding Buffer. Following the addition of 5 μl
fluorochrome-conjugated Annexin V staining solution to
100 μl cell suspension, cells were incubated in the dark for
15 minutes at room temperature and evaluated for apop-
tosis on a flow cytometer from Becton Dickinson (San Jose,
CA). Negative controls included cells with vehicle (DMSO)
stained for Annexin V and cells without staining.
Cell cycle analysis
Cell cycle distribution was evaluated by using propidium
iodide staining and the BD FACSCanto II system (San
Jose, CA). Cells were arrested in G1/S phase by employ-
ing a double thymidine block (2 mM) from Sigma Al-
drich (St. Louis, MO). The following day, the reaction
was halted by replacing media with fresh thymidine con-
taining media and cells were collected at varying time
points thereafter. Once the cell pellets were collected,
they were washed with 1X PBS (pH 7.2) from Life Tech-
nologies (Carlsbad, CA) and fixed with ice cold 80%
ethanol from Commercial Alcohols (Tiverton, ON). We
used 0.1 mg/ml propidium iodide and 2 mg/ml RNase A
purchased from Sigma Aldrich (St. Louis, MO) which
were added to each sample prior to incubation in the
dark for 30 minutes. The cell cycle data were collected
using the BD FACSCanto II system and analyzed using
FlowJo software (San Jose, CA).
Microarray sample submission
Illumina Human HT-12-V4 Bead Chips were used for
the whole genome microarray analysis by the University
Health Network (UHN) Microarray Centre in Toronto,
Canada. Total RNA was extracted with the RNeasy Mini
kit from Qiagen (Toronto, ON) and used for profiling
gene expression changes.
Gene expression analysis
Summary-level data from GenomeStudio (defaulted to
have no normalization or background correction) were
loaded into the R statistical environment (v3.0.2) using
the lumi package (v2.12.0) from BioConductor [13]. The
remaining samples were transformed using variance-
stabilizing transformation (VST) and normalized using
robust spline normalization. Samples from the same cell
lines (native and drug resistant) were pre-processed to-
gether to avoid confounding effects from normalizing
multiple cell lines together. Following pre-processing,
we used general linear-modeling to identify genes that
are differentially expressed in drug resistant cell lines
relative to native cell line controls. The gene expression
levels across all cell lines were determined using a per-
gene linear model that assessed both basal levels and
drug resistance-induced effects. Coefficients were fitted
to terms representing each effect and the standard errors
of the coefficients were adjusted using an empirical
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Bayes moderation of the standard error [14]. To test if
each coefficient was statistically different from zero, we
applied model-based t-tests, followed by a false discovery
rate (FDR) adjustment for multiple testing [15]. Genes
were deemed to be significant if their adjusted p-values
were less than or equal to 0.05. All statistical analyses
were performed using the limma package (v3.16.8)
within the R statistical environment (v3.0.2). Genes
showing significant differential gene expression levels
between the resistant and native samples across all types
of cell lines were loaded into the Cytoscape Reactome
Functional Interaction (FI) plugin in Cytoscape (v3.0.2).
Symbols were loaded as a gene set with the 2013 version
of the FI network. FI network was constructed with FI
annotations and linker genes. Spectral clustering and
Pathway Enrichment were computed for each module
using the Reactome FI plugin functions and the path-
ways exhibiting FDR < 0.05 were considered enriched.
Immunoblot analysis
Cell lysates were normalized using the BCA Protein
Assay Kit by Pierce and equivalent amounts of total pro-
tein were separated by electrophoresis on 4-20% BioRad
Mini Protean TGX Precast Gels (Hercules, CA). Gels
were transferred to nitrocellulose membranes and incu-
bated with rabbit anti-cyclin B1 (1:1000 dilution) from
Cell Signaling (Danvers, MA), mouse anti-BubR1 (1:
1000 dilution) from BD Transduction Laboratories (San
Jose, CA), rabbit anti-CENPE (1:2000 dilution) from
Sigma (Oakville, ON), and rabbit anti-CENPF (1:1000
dilution) from Novus Biologicals (Oakville, ON) anti-
bodies. The visualization of blots was performed using
the ChemiDoc Imaging System and accompanying
Image Lab software from BioRad (Hercules, CA). The
membranes were stripped and re-probed for β-actin (1:
10,000 dilution) from Proteintech Group (Rosemont, IL)
which served as a loading control.
Results
Increased resistance to paclitaxel, docetaxel and
anthracyclines in human ovarian cancer cells
To study chemotherapeutic resistance in ovarian cancer
cells, we established three paclitaxel resistant cell lines
by incremental and continuous exposure to paclitaxel,
up to a final concentration of 25 nM. We observed
marked increases in IC50 values for both paclitaxel and
docetaxel (up to 75 fold) in all 3 cell lines representing
three different histologic subtypes (Table 1). In addition,
we observed distinct cross-resistance to anthracyclines,
including epirubicin and doxorubicin (typically 3-10
fold) across all 3 cell line pairs (Table 1). Carboplatin is
currently a standard treatment option, and we show
cross-resistance to carboplatin in the TOV112D cell line,
which may indicate improved clinical benefit in the
endometrioid ovarian subtype (Table 1).
Reduced cell apoptosis in paclitaxel resistant human
ovarian cancer cells
During exposure of native and resistant cell lines to in-
creasing concentrations of paclitaxel, we demonstrated that
paclitaxel resistant cell lines exhibited reduced cell apop-
tosis relative to their native counterparts, following expos-
ure to 25 and 1000 nM paclitaxel treatment (Table 2). For
example, the percentage of apoptotic cells in the native
TOV21G ovarian cells was 59% versus 14% in the resistant
cells, following the addition of 25 nM paclitaxel. This result
was equally marked in the TOV112D ovarian cells where
63% of native cells were apoptotic versus 4% in the resist-
ant cell line. Lastly, a similar trend was observed in the
COV504 ovarian cells where 26% of the native cells were
apoptotic compared to 10% of the resistant ovarian cells in
the presence of 25 nM paclitaxel. The treatment of resist-
ant ovarian cell lines with 25 nM paclitaxel clearly resulted
in reduced cell apoptosis across all subtypes observed.
Paclitaxel resistant human ovarian cells overcome G2/M
arrest
We monitored cell cycle progression in both the native
and resistant ovarian cell lines (±) 25 nM paclitaxel and
we found that the resistant cell lines were able to over-
come paclitaxel induced G2/M arrest and progress
through the cell cycle. At 12 hours, paclitaxel treatment
of the native TOV21G, TOV112D and COV504 cells
caused a G2/M block and a failure to progress to the
G0/G1 phase (Fig. 1). Specifically, the G2/M population
of TOV112D native cells increased considerably from
26% to 55% upon exposure to paclitaxel, indicating mi-
totic arrest in G2/M, compared with a minimal change
of 29% to 36% in the TOV112D resistant cells. The in-
crease in cell accumulation at the G2/M phase was ac-
companied by a decrease of cell population in the G1
phase for the native cells. Similar results were observed
in the COV504 resistant cell line, whereby the G1 popu-
lation changed minimally from 35% to 36% following
paclitaxel treatment. These results verify that paclitaxel
inhibits cell growth by inducing a block at G2/M phase
in several subtypes of ovarian cancer cells, however this
effect is more apparent in the native cell lines rather
than the resistant cell lines, and overcoming G2/M ar-
rest is a potential process linked to paclitaxel resistance.
Gene expression analysis in paclitaxel resistant human
ovarian cancer cells
The effect of paclitaxel resistance across several subtypes
was examined and a number of statistically significant
alterations in gene expression levels (q ≤ 0.05) were ob-
served between the native and paclitaxel resistant cells
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(Fig. 2). These changes in gene expression include 49
deregulated genes across the ovarian histologic subtypes.
Among the differentially expressed genes were a number
of key regulators that maintain the mitotic spindle
checkpoint. Specifically, we determined that 21 genes
were found depleted when compared to the native cell
lines (Additional file 1: Table S1), and many of these
genes were associated with cell cycle regulation and the
mitotic checkpoint, and include the following: Aurora
kinase A (AURKA), abnormal spindle microtubule as-
sembly (ASPM), BUB1, CCNB1, CENPE, and CENPF
and NIMA-related kinase 2 (NEK2). Alternatively, gene
enrichment patterns were observed in several functions
controlling structural scaffolding and development and
apoptotic control; these genes include BCL2/adenovirus
E1B 19 kDa interacting protein 3 (BNIP3), sprouty
homolog 2 (SPRY2), and the WW domain binding pro-
tein 5 (WBP5). Overall, several genes governing G2/M
transition were found depleted and to ultimately affect
mitotic function, corresponding to acquired paclitaxel
resistance in ovarian cell lines.
Pathway analysis in paclitaxel resistant human ovarian
cancer cells
We explored pathway analysis and observed several gene
alterations between resistant cells and their respective
native cell lines (q ≤ 0.05) (Fig. 3). The majority of gene
nodes display gene depletion and include the following
candidate genes: AURKA, ASPM, NEK2, BUB1, CCNB1,
CENPE and CENPF. Reactome network analysis revealed
significant pathways and genes associated with mitotic
regulation, and these include: (1) mitotic pro metaphase
(2) mitotic metaphase and anaphase (3) mitotic G2-G2/
M phase and (4) APC/C-mediated degradation of cell
cycle proteins (Table 3). An additional pathway linked to
the spindle checkpoint control involves ubiquitin conju-
gating enzyme E2C (UBE2C) which was found depleted
across the ovarian subtypes. Cell cycle progression was
shown to be modified by UBE2C which can affect the
degradation of cyclin B1 required for mitotic exit [16].
Validation of reduced protein expression in paclitaxel
resistant human ovarian cancer cells
Immunoblotting of ovarian cancer cells revealed a de-
crease in spindle assembly checkpoint proteins in the
paclitaxel resistant cells (Fig. 4). Specifically, there was a
marked decrease in both BUB1-related protein (BubR1)
and cyclin B1 protein expression in the paclitaxel resist-
ant cells versus the corresponding natives. Our results
support previous work illustrating lower expression of
BubR1 and cyclin B1 in paclitaxel resistant ovarian cells
OVCAR-3 and SKOV-3 versus their corresponding na-
tive cells, thus validating our functional data [8]. Fur-
thermore, a significant decrease in CENPE and CENPF
protein expression was observed in the paclitaxel resist-
ant cells versus the corresponding native cells (Fig. 4).
Table 2 Percentages of apoptotic ovarian cells following the
absence or presence of paclitaxel
DMSO Paclitaxel (25nM) Paclitaxel (1000 nM)
TOV21G N 6.00 58.60 63.00
(±0.38) (±4.50) (±2.80)
TOV21G R 11.20 13.601 56.70
(±5.50) (±1.10) (±30.70)
TOV112D N 1.80 63.20 82.00
(±0.18) (±0.50) (±0.25)
TOV112D R 2.00 3.702 69.00
(±0.27) (±0.57) (±0.87)
COV504 N 7.40 25.70 49.60
(±4.40) (±6.70) (±25.30)
COV504 R 8.40 10.003 29.60
(±4.40) (±1.80) (±6.20)
Annexin V staining was used to determine the early detection of apoptotic cells
and after 72 hours, apoptosis is evident in both native (N) and paclitaxel resistant
(R) cell lines, in all three subtypes TOV21G, TOV112D and COV504. Both
the native and resistant cell lines were exposed to increasing concentrations of
paclitaxel; all three paclitaxel resistant cell lines exhibited reduced apoptotic
induction when exposed to 25 and 1000 nM paclitaxel treatment (± standard
deviation, average of 3 independent experiments). 1(p < 0.01) 2(p < 0.04)
3(p < 0.05) versus corresponding native groups
Table 1 The half maximal inhibitory concentration (IC50) in human ovarian cancer cells
Paclitaxel (nM) Docetaxel (nM) Epirubicin (nM) Doxorubicin (nM) Carboplatin (uM)
TOV21G N 1.31 ± 0.75 0.17 ± 4.43 6.30 ± 1.90 0.02 ± 1.01 17.99 ± 1.27
TOV21G R 44.64 ± 15.41 (34) 10.73 ± 1.28 (63) 20.06 ± 1.48 (3) 9.90 ± 1.72 (495) 0.59 ± 4.64
TOV112D N 1.49 ± 1.40 0.86 ± 1.50 9.60 ± 1.10 11.19 ± 1.11 80.81 ± 1.08
TOV112D R 28.26 ± 1.06 (19) 13.91 ± 1.11 (16) 34.78 ± 1.10 (3.6) 30.16 ± 1.09 (3) 140.0 ± 1.45 (2)
COV504 N 1.91 ± 1.85 0.30 ± 3.37 31.56 ± 1.48 47.58 ± 1.81 103.68 ± 1.14
COV504 R 75.51 ± 27.44 (40) 23.08 ± 1.25 (77) 290.33 ± 2.20 (9) 250.58 ± 2.50 (5) 35.16 ± 1.35
The IC50 in both native (N) and drug resistant (R) ovarian cancer cell lines were determined by incremental and continuous exposure to drug. Drug resistance is
clearly defined in all subtypes and most evident in the epithelial serous cell line, represented by COV504 for both taxanes and anthracyclines (± standard
deviation, average of 3 independent experiments). The resistance factor is shown in parentheses and highlights drug resistance (resistant IC50/native IC50) for each
cell line pair
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Clinical tumour samples and kaplan-meier survival curve
analysis
The Cancer Genome Atlas (TCGA) is a large scale data-
base containing human cancer genomics data [17, 18]. We
have analyzed our candidate genes using the TCGA clin-
ical database and web based tool cBio Cancer Genomics
Portal (http://www.cbioportal.org/), which was developed
for mining cancer genome sequencing data [17, 18]. We
have evaluated the mRNA expression of primary serous
ovarian tumour samples via Agilent microarray to validate
the impact of candidate genes BUB1, CCNB1, CENPE and
CENPF on overall survival. Using Kaplan-Meier survival
curve analysis, we have found that overall survival of 489
patients was significantly less (p < 0.02) when the candi-
date genes were deregulated (Fig. 5). Moreover, patient
prognosis with altered expression was significantly poorer
than those with unaltered mRNA expression.
Discussion
Our study revealed gene depletion across a number of
molecular components involved in the spindle assembly
checkpoint and mitotic regulation, including BUB1,
CCNB1, CENPE and CENPF in paclitaxel resistant ovar-
ian cancer cell lines. We found molecular pathways
involving mitotic regulation, mitotic pro metaphase, mi-
totic anaphase and mitotic G2-G2/M phase showing sig-
nificant depletion. Using the TCGA clinical database, we
have shown that altered expression of candidate genes in
patients with serous ovarian cancer contributes to signifi-
cantly poorer survival status in patients. Taken together,
we have found evidence of a deregulated spindle assembly
checkpoint with significant alteration in mitotic regulators
linked to the acquisition of paclitaxel resistance across
ovarian subtypes. Several chemotherapeutic agents, such
as paclitaxel, target the spindle assembly checkpoint which
affects mitotic progression and arrest, thus emphasizing
(See figure on previous page.)
Fig. 1 Cell cycle distributions in native and paclitaxel resistant cell lines (a) TOV21G, (b) TOV112D and (c) COV504. Using a double thymidine
block, native and paclitaxel resistant cells were synchronized and incubated in the presence of DMSO or 25 nM paclitaxel. Cells were collected at
12 hours and the cell cycle distributions within the cell population were analysed by flow cytometry. The cellular response of 3 cell lines was
consistent whereby the resistant ovarian cancer cells treated with paclitaxel were able to overcome paclitaxel induced G2/M arrest and
progressed through the cell cycle. The percentages shown represent a single experiment; 3 independent experiments were conducted for each
cell line
Fig. 2 Venn diagram showing overlapping genes between the
paclitaxel resistant cell lines. Paclitaxel resistant cell lines TOV21G,
TOV112D and COV504 were differentially expressed across multiple
histologic subtypes (q ≤ 0.05). The changes in mRNA abundance
include an overlap of 49 significant genes highlighting both
enrichment and depletion of genes across human ovarian cell lines
Fig. 3 Pathway analysis illustrating differential gene expression and
association between gene nodes. The gene nodes display gene
depletion (q ≤ 0.05) and include the following candidate genes:
BUB1, CCNB1, CENPE and CENPF. The arrows with blunt ends
denote negative regulation and sets with overlapping content
are connected by a line of long dashes. The arrows represent
positive regulation
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the importance of the mitotic spindle and associated genes
as a therapeutic target [19–21].
Cyclin B1 and cyclin dependent kinases (cdks) are associ-
ated with mitosis and cell cycle regulation [8, 22]. Our gene
expression data reveal significant depletion of cyclin B1
across all three resistant ovarian subtypes. Our findings are
consistent with recent data showing reduced cyclin B1 pro-
tein expression in two additional paclitaxel resistant ovarian
cell lines, OVCAR-3 and SKOV-3 versus their respective
parental cell lines [8, 19]. Furthermore, a functional de-
crease in cyclin B1 protein expression was observed in
conjunction with reduced CDK1 (cdc2) expression in
human ovarian cisplatin resistant A2780 cells [22]. Since
cyclin B1 is a marker specific for the G2/M phase, the de-
crease in cyclin B1 is associated with the deregulation and
weakening of the G2/M phase of the cell cycle [19]. There-
fore, a functional loss of cyclin B1 can be attributed to the
destabilization of the spindle checkpoint, thus emphasizing
the role of cyclin B1 on cell cycle dynamics and the regula-
tory mechanisms associated with paclitaxel resistance.
Cell cycle progression is tightly orchestrated and many
of the spindle assembly checkpoint genes associated with
regulation, including BUB1 and BUBR1 are conserved
throughout evolution [19, 23]. BUB1 is a molecular
component of the spindle checkpoint and required for
proper checkpoint signalling and deletions of BUB1 or
BUBR1 were detected in several cancers [12, 24]. Previ-
ously, mitotic checkpoint defects and the inactivation of
the BUB1 gene have been implicated in human colorec-
tal cancer cells [12, 25]. These colorectal cell lines with
loss of altered checkpoint function were also found to
show chromosomal instability [12]. Consistent with this
Table 3 Reactome network analysis revealing significant association with mitotic regulation
Associated Pathway Genes FDR
mitotic pro metaphase CCNB1, CKAP5, BUB1, CENPF, CENPE, NDC80 FDR ≤ 3.33 x 10-4
mitotic metaphase and anaphase CKAP5, LMNA, BUB1, CENPF, CENPE, NDC80, UBE2C, PSME1 FDR ≤ 1.00 x 10-3
mitotic G2-G2/M phase CCNB1, CKAP5, NEK2, CENPF, AURKA FDR ≤ 1.00 x 10-3
APC/C-mediated degradation of cell cycle proteins AURKA, UBE2C, CCNB1, PSME1 FDR ≤ 4.80 x 10-3
Reactome network analysis revealed pathways associated with mitotic regulation. These networks predominantly involve spindle assembly checkpoint, centromere-
kinetochore complex and cell cycle regulation
Fig. 4 The effect of paclitaxel resistance on key regulators of the
mitotic spindle checkpoint. Immunoblot analysis of cell cycle proteins
BubR1, cyclin B1, CENPE and CENPF isolated from native and resistant
cell lines. Individual lanes contained 20-50 μg of total protein; each gel
was normalized. The proteins were resolved on 4-20% Mini Protean
TGX Precast Gels, transferred to nitrocellulose membranes and probed
using antibodies specific for BubR1, cyclin B1, CENPE and CENPF
proteins. β-actin served as a loading control. The immunoblots represent
a single experiment; 3 independent experiments were conducted
Fig. 5 Kaplan-Meier survival curve analysis in primary serous ovarian
tumours. Kaplan-Meier survival analysis comparing the mRNA status
with overall survival in 489 primary serous ovarian tumour samples.
Z-Scores of mRNA expression of candidate genes were downloaded
using cBioPortal. Survival status was significantly poorer in patients
with altered expression of all 4 candidate genes (p < 0.02)
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finding, one study examining a subset of human colorec-
tal tumours revealed a statistically significant association
of low BUB1 and BUBR1 mRNA expression with in-
creased metastasis, and a higher recurrence rate [26]. A
corresponding observation found BubR1 protein expres-
sion was considerably reduced in polyploid cells, and in
31.3% (21/67) of the human colon adenocarcinoma ex-
amined [27]. Collectively, these results illustrate that de-
regulation of the spindle assembly checkpoint is
associated with the lack of BUB1 gene function and this
deficiency is associated with paclitaxel resistance.
Kinetochore motor proteins CENPE and CENPF are
required for proper microtubule attachment and regula-
tion of the spindle checkpoint [23, 28]. Our results re-
veal significant depletion of CENPE and CENPF mRNA
levels across the ovarian subtypes when compared to na-
tive cells. In support of our findings, recent evidence
shows CENPF siRNA knockdown resulting in cisplatin
resistance in a variant small cell lung carcinoma and a
non-small cell lung adenocarcinoma [29]. Similar obser-
vations reveal depletion of CENPE resulting in unstable
kinetochore-microtubule capture and chromosomal in-
stability [30]. Furthermore, evidence illustrated reduced
CENPE mRNA expression found in a human hepatocellu-
lar carcinoma (HepG2) versus a normal liver cell line
(LO2); the results were further validated using western
blot analysis and quantitative real-time PCR [31]. In vitro
immunofluorescence staining demonstrated that CENPE
is co-localized with BUBR1 at kinetochores [28]. The dir-
ect interaction between the centromere-kinetochore com-
plex and BUBR1, along with spindle microtubules is
believed to modulate mitotic checkpoint signaling events
and thus highlights the interaction of kinetochores, spin-
dle checkpoint control and mitotic progression [24].
Conclusions
We have generated model systems to explore drug re-
sistance in ovarian cancer, which reveal a defective
spindle assembly checkpoint associated with acquired
paclitaxel resistance. Our results demonstrate that deple-
tion of spindle checkpoint related genes BUB1, CCNB1,
CENPE and CENPF during paclitaxel resistance corre-
lates with significant disruption to the cell cycle, which
can lead to the suppression of paclitaxel induced cell
death. Specifically, multiple cancers exhibit gene down
regulation involving CCNB1 and BUB1, highlighting the
relationship between a disrupted spindle assembly
checkpoint and tumour formation. Since paclitaxel is an
effective microtubule drug and exerts apoptotic effect
through the regulation of the spindle assembly check-
point, restoration of gene function to spindle checkpoint
related genes would seem an effective target for minim-
izing cancer progression.
Additional file
Additional file 1: Table S1. List of significant genes illustrating enrichment
and depletion of genes across 3 ovarian cancer cell lines. (XLS 38 kb)
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